Perspective Therapeutics to present data at EANM congress

Perspective Therapeutics will present new clinical and preclinical data for 212Pb-VMT-alpha-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine. The conference is being held in Vienna, Austria, from September 9-13, 2023. Presentation One: This presentation will discuss early clinical results from the study of 212Pb-VMT-alpha-NET in ten patients with somatostatin receptor-expressing progressive neuroendocrine tumors and metastatic medullary thyroid carcinomas. 212Pb-VMT-alpha-NET demonstrated an encouraging safety profile and treatment resulted in partial responses in a number of patients. Title: Early results of 212Pb-VMT-alpha-NET Targeted Alpha Therapy in Metastatic Gastro-entero-pancreatic Neuroendocrine Tumors: First in Human Clinical Experience on Safety and Efficacy. Presentation Two: This presentation will discuss the effective tumor control of fractionated doses of (212Pb)VMT-alpha-NET demonstrated in a mouse model of high-risk metastatic neuroblastoma. The data showed that fractionated doses of (212Pb)VMT-alpha-NET provided greater benefit than single dose administration of (212Pb)VMT-alpha-NET. Title: Preclinical Evaluation of (212Pb)VMT-alpha-NET Targeted Alpha Therapy for High-Risk Metastatic Neuroblastoma